T1	Participants 137 161	metastatic breast cancer
T2	Participants 284 323	patients with metastatic breast cancer,
T3	Participants 876 996	over-accrual of 475 patients, the trial matured with only 324 of 385 planned TtP events due to patient discontinuations.